RBC Cuts BioMarin Price Target to $60 From $62
RBC Capital Markets maintained its Sector Perform rating. The change follows BioMarin's Q3 2026 report and downward revision to 2026 financial guidance.
RBC Capital Markets maintained its Sector Perform rating. The change follows BioMarin's Q3 2026 report and downward revision to 2026 financial guidance.